IMBdx Valuation Multiples

Discover revenue and EBITDA valuation multiples for IMBdx and similar public comparables like Abingdon Health, Bioretec, Cleo Diagnostics, Q-linea and more.

IMBdx Overview

About IMBdx

IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.


Founded

2018

HQ

South Korea

Employees

N/A

Website

imbdx.com

Financials (FY)

Revenue: $4M
EBITDA: ($5M)

EV

$22M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

IMBdx Financials

IMBdx reported last fiscal year revenue of $4M and negative EBITDA of ($5M).

In the same fiscal year, IMBdx generated $979K in gross profit, ($5M) in EBITDA losses, and had net loss of ($6M).


IMBdx P&L

In the most recent fiscal year, IMBdx reported revenue of $4M and EBITDA of ($5M).

IMBdx is unprofitable as of last fiscal year, with gross margin of 26%, EBITDA margin of (122%), and net margin of (149%).

See analyst estimates for IMBdx
Last FY202320242025202620272028
Revenue$4M$3M$2M$4M
Gross Profit$979K$1M$627K$979K
Gross Margin26%35%26%26%
EBITDA($5M)($6M)($6M)($5M)
EBITDA Margin(122%)(194%)(233%)(122%)
EBIT Margin(163%)(193%)(311%)(163%)
Net Profit($6M)($7M)($7M)($6M)
Net Margin(149%)(259%)(281%)(149%)

Financial data powered by Morningstar, Inc.

IMBdx Stock Performance

IMBdx has current market cap of $35M, and enterprise value of $22M.


IMBdx's stock price is $2.47.

IMBdx has an EPS (earnings per share) of $-0.39.

See more trading valuation data for IMBdx
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$22M$35M-0.9%---$-0.39

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

IMBdx Valuation Multiples

IMBdx trades at 5.9x EV/Revenue multiple, and (4.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for IMBdx

IMBdx Financial Valuation Multiples

As of August 14, 2026, IMBdx has market cap of $35M and EV of $22M.

IMBdx has a P/E ratio of (6.3x).

Last FY202320242025202620272028
EV/Revenue5.9x7.7x9.2x5.9x
EV/EBITDA(4.8x)(4.0x)(3.9x)(4.8x)
EV/EBIT(3.6x)(4.0x)(2.9x)(3.6x)
EV/Gross Profit22.5x22.0x35.1x22.5x
P/E(6.3x)(4.8x)(5.2x)(6.3x)
EV/FCF(4.3x)(4.6x)(4.1x)(4.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified IMBdx Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

IMBdx Margins & Growth Rates

In the most recent fiscal year, IMBdx reported gross margin of 26%, EBITDA margin of (122%), and net margin of (149%).

See estimated margins and future growth rates for IMBdx

IMBdx Margins

Last FY20242025202720282029
Gross Margin26%26%26%
EBITDA Margin(122%)(233%)(122%)
EBIT Margin(163%)(311%)(163%)
Net Margin(149%)(281%)(149%)
FCF Margin(135%)(222%)(135%)

IMBdx Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(15%)56%
Gross Profit Growth(37%)56%
EBITDA Growth2%(19%)
EBIT Growth37%(18%)
Net Profit Growth(8%)(17%)
FCF Growth12%(5%)

Data powered by FactSet, Inc. and Morningstar, Inc.

IMBdx Operational KPIs

Access forward-looking KPIs for IMBdx
Last FY202320242025202620272028
S&M Expenses to Revenue15%35%41%15%
G&A Expenses to Revenue9%4%7%9%
R&D Expenses to Revenue96%143%207%96%
Opex to Revenue189%228%338%189%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

IMBdx Competitors

IMBdx competitors include Abingdon Health, Bioretec, Cleo Diagnostics, Q-linea, Nortech Systems, EOFlow Co, Baird Medical Investment, Mauna Kea Technologies, Ortoma and Elutia.

Most IMBdx public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Abingdon Health2.8x2.1x(8.4x)(18.3x)
Bioretec7.8x6.0x(3.3x)(3.6x)
Cleo Diagnostics----
Q-linea15.5x-(1.1x)-
Nortech Systems0.4x-23.5x-
EOFlow Co18.3x-(2.9x)-
Baird Medical Investment2.5x-(2.3x)-
Mauna Kea Technologies4.5x4.6x2.8x(10.7x)

This data is available for Pro users. Sign up to see all IMBdx competitors and their valuation data.

Start Free Trial

IMBdx VC Funding History

Before going public, IMBdx raised $28M in total equity funding, across 3 rounds.


IMBdx Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
May-21Series B-$18M-IMB Dx raised a total of $25.45M across 4 funding rounds, with its latest being a Series B round of $18.37M on May 12, 2021.
Apr-20Series A-$8M--
Mar-19Seed-$2M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About IMBdx

When was IMBdx founded?IMBdx was founded in 2018.
Where is IMBdx headquartered?IMBdx is headquartered in South Korea.
Is IMBdx publicly listed?Yes, IMBdx is a public company listed on Korea Exchange.
What is the stock symbol of IMBdx?IMBdx trades under 461030 ticker.
When did IMBdx go public?IMBdx went public in 2024.
Who are competitors of IMBdx?IMBdx main competitors include Abingdon Health, Bioretec, Cleo Diagnostics, Q-linea, Nortech Systems, EOFlow Co, Baird Medical Investment, Mauna Kea Technologies, Ortoma, Elutia.
What is the current market cap of IMBdx?IMBdx's current market cap is $35M.
What is the current revenue of IMBdx?IMBdx's last fiscal year revenue is $4M.
What is the current EV/Revenue multiple of IMBdx?Current revenue multiple of IMBdx is 5.9x.
Is IMBdx profitable?No, IMBdx is not profitable.
How many companies IMBdx has acquired to date?IMBdx hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies IMBdx has invested to date?IMBdx hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to IMBdx

Lists including IMBdx

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial